Got to hear most of the Q&A. Best question was why despite all sounding positive optimistic still lack of institutional investors and weak Sp- CEO response vague. my notes: Q: When is OSL getting Exec medic as not had one for 18 months. A: we’re looking to hire but CEO has been acting as medic
Q: any pushback by docs to device? A: no, only on non —approval to use device with folfirinox chemo which is preferred chemo in Europe (this was interesting, didn’t realise bsi must have knocked that back, CEO seemed to think not a big issue)
Q: working with nhs and uk reimbursement: A: lots going on in UK, patients being screened, they expect it’ll be funded on back of strength of data , can’t divulge price
Q: status of Panco trial A: ongoing, will publish /present, they expect survival in resection patients to match what has been seen at john Hopkins in US , >30 months median. Otherwise no new info provided on trial.
OSL Price at posting:
11.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)